{"id":"art0380","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Gastrointestinal toxicity"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL5505926","moleculeType":null,"molecularWeight":"388.50"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"ART0380 targets the DPC repair pathway, which cells normally use to remove DNA-protein crosslinks caused by chemotherapy and other DNA-damaging agents. By inhibiting this repair mechanism, the drug potentiates the cytotoxic effects of DNA-damaging therapies, making cancer cells more susceptible to treatment. This approach is designed to improve efficacy of existing chemotherapies and overcome resistance mechanisms.","oneSentence":"ART0380 is a DNA-protein crosslink (DPC) repair inhibitor that enhances the activity of DNA damaging agents by preventing cellular repair of crosslinks.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:11:34.648Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced solid tumors (in combination with DNA-damaging chemotherapy)"}]},"trialDetails":[{"nctId":"NCT04657068","phase":"PHASE1, PHASE2","title":"A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Artios Pharma Ltd","startDate":"2021-01-27","conditions":"Advanced Cancer, Metastatic Cancer, Ovarian Cancer","enrollment":442},{"nctId":"NCT05798611","phase":"PHASE2","title":"Study of ART0380 in Patients With Biologically Selected Solid Tumors","status":"TERMINATED","sponsor":"Artios Pharma Ltd","startDate":"2023-09-06","conditions":"Advanced Solid Tumor, Recurrent Endometrial Cancer, Metastatic Cancer","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ART0380","genericName":"ART0380","companyName":"Artios Pharma Ltd","companyId":"artios-pharma-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ART0380 is a DNA-protein crosslink (DPC) repair inhibitor that enhances the activity of DNA damaging agents by preventing cellular repair of crosslinks. Used for Advanced solid tumors (in combination with DNA-damaging chemotherapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}